via University of Reading
An antioxidant drug reverses atherosclerosis and could be used to prevent heart attacks and strokes due to clots, according to research funded by the British Heart Foundation (BHF) and published today in JAHA: Journal of the American Heart Association.
Atherosclerosis is the build-up of fatty deposits in the arteries. When a type of fat called LDL cholesterol becomes oxidised and builds up to form plaques in the artery walls, inflammation and damage increase which can cause the plaques to rupture and cause blood to clot.
These clots can block vital arteries that allow blood to flow to the heart, causing a heart attack, or to the brain causing a stroke.
Previously, researchers at the University of Reading discovered that LDL cholesterol can be oxidised in acidic small ‘bags’ called lysosomes in immune cells within the artery wall.
Now, Professor David Leake and his team have found that the antioxidant drug, cysteamine, has the power to switch off, and even reverse, this damaging process.
Cysteamine works by accumulating in the lysosomes and stops the oxidation of LDL cholesterol. It is already known to be safe in humans where it’s used to treat a rare lysosomal disease called cystinosis.
When the researchers looked at mice with atherosclerosis, those treated with cysteamine had a 32 to 56 per cent reduction in the size of atherosclerotic plaques depending on the part of the aorta – the largest artery in the body – that was examined.
Cysteamine decreased the amount of oxidised fat by 73 per cent and increased the stability of the atherosclerotic areas. It decreased the proportion of inflammatory white blood cells by 55 per cent and increased the area made up of smooth muscle cells by 85 per cent, ultimately reducing the chance of plaques rupturing and causing a blood clot.
Antioxidant drugs that have previously produced promising results in mice have proven disappointing in clinical trials to treat cardiovascular disease, but the researchers hope that with these promising results, cysteamine will prove a successful treatment in humans.
Professor David Leake, Professor of Biomedical Sciences at the University of Reading who led the study said:
“The potential in this drug to protect against heart attacks and strokes and ultimately save lives superseded our expectations. We hoped it would cause plaques to grow at a slower pace, but we were amazed to find it reversed the process.
“Cysteamine would offer an entirely new way of treating atherosclerosis. We now want to look at the most efficient way to give this drug to patients, and hope that it can be taken to clinical trials in the next few years.”
Professor James Leiper, Associate Medical Director at the British Heart Foundation, which funded the research said:
“Heart attacks and strokes threaten the lives of people too often. In the UK, every 5 minutes someone is admitted to hospital with a heart attack, and the same is true of stroke. “The more ways we can find to treat the root cause of cardiovascular disease, the more lives and livelihoods that can be saved.
“If this antioxidant drug can show the same promising effects in humans, then it could offer a lifeline to thousands of people in the future.”
Original Article: ANTIOXIDANT DRUG REVERSES PROCESS RESPONSIBLE FOR HEART ATTACKS AND STROKES
More from: University of Reading
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cysteamine
- Fashion and Beauty: The heroes (must-haves) of spring beautyon April 18, 2024 at 4:00 am
A new season means adding a few new products to your beauty arsenal. Whether it's something to help lengthen lashes, plump up your pucker, or getting on your pre-summer glow, ...
Go deeper with Google Headlines on:
Cysteamine
[google_news title=”” keyword=”cysteamine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Treating atherosclerosis
- Global Atherosclerosis Industry is expected to reach US$ 59,514.3 Million, growing at a consistent CAGR of 2.8% | FMIon April 23, 2024 at 8:13 am
The Global Atherosclerosis Industry is on track for significant expansion, with a projected Compound Annual Growth Rate (CAGR) of 2.8% from 2023 to 2033. This translates to a market valuation of US$59 ...
- Spanish scientists identify the key cell type for strategies to prevent atherosclerosis in progeria syndromeon April 22, 2024 at 12:21 pm
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic disease that affects just 1 in every 20 million people; it is estimated that fewer than 400 children in the world have the ...
- Vascular Proliferation and Atherosclerosis: New Perspectives and Therapeutic Strategieson April 20, 2024 at 5:00 pm
Atherosclerosis involves multiple processes ... Thus, an emerging strategy for the treatment of those conditions is to inhibit cellular proliferation by targeting cell cycle regulation.
- Vaccines targeting chronic diseases show promise in combatting age-related conditionson April 17, 2024 at 3:32 am
Vaccines for age-related vascular diseases such as hypertension, abdominal aortic aneurysm (AAA), and atherosclerosis target molecules that regulate blood pressure, cholesterol, and blood vessel ...
- Is Hormone Replacement Therapy for Menopause *Also* Good for Your Heart? It Could Come Down to Timingon April 14, 2024 at 4:30 am
Hormone replacement therapy (or HRT) can help reduce menopause symptoms, but some studies suggest it may protect your heart as you age, too. Learn more about the HRT and heart disease connection here.
Go deeper with Google Headlines on:
Treating atherosclerosis
[google_news title=”” keyword=”treating atherosclerosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]